The positive effects of the treatment of cellulite with the Centella Asiatica Extract were confirmed in the following 4 clinical studies.
A double-blind trial, involving 35 patients evaluated the size of fat cells in the thigh and shoulder regions. Twenty people participating in the experiment were administered 60 mg of the dry extract of C. asiatica orally once a day, for 90 days. Other participants of the experiment group took a placebo. The results showed that in the patients taking the Centella Asiatica Extract, the diameter of fat cells decreased in both studied regions of the body with a predominance of positive changes in the thigh region.
In the experiment on a group of 60 people with cellulite, Centella Asiatica Extract applied four times a day for 4 months was studied. The results clearly showed a beneficial effect of the Gotu Kola extract on inhibiting the progression of cellulite and a significant improvement in the skin condition in 85% of the experiment participants.
Other experiments conducted on 65 patients with advanced cellulite showed that oral intake of Centella Asiatica Extract together with simultaneous reduction in diet for 3 months caused a significant decline in cellulite in 58% of the patients, whereas in 20% of the volunteers the effects were only satisfactory.
A randomized, double-blind, placebo-controlled trial of a Centella Asiatica Extract cream, which also included Vitamin E, hydrolyzed collagen and elastin, was carried out on 100 pregnant women. Half of the women, who qualified for the study, received a placebo, the other half were applied a tested cosmetic preparation. The cream was applied daily on breasts, abdomen, buttocks and hips, starting from the third month of pregnancy. The results indicated that in the placebo group, striae occurred in 56% of the women (22 patients), whereas in the group that used the cream with the extract of Centella Asiatica Extract, the problem affected 14 women only. The tested cream provided significant protection for the women who had had cellulite during puberty (89% of the women).